Thank you
This live web event has ended. Thank you for attending.
Description
Patients with PAH still face a devastating and progressive
disease. This program will review the imbalances in BMPR-II and activin
receptor signaling that may drive PAH progression, and will focus on an
investigational therapeutic approach that aims to rebalance this signaling in
the context of the latest data from ongoing clinical trials.
This program is sponsored by Acceleron.
By registering for this
webinar, you agree your information will be shared with the sponsor.
No CME or MOC credits are
available for this program.
Opinions expressed and
resources shared may not have been reviewed by the ATS prior to distribution
through ATS channels, or reflect official positions of the ATS, unless it is
explicitly noted as a result of official ATS approval. References to specific commercial
entities (companies) or products do not reflect review or endorsement by the
ATS unless it is explicitly noted as a result of official ATS approval.